Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Gillessen S, et al. Among authors: olmos d. Ann Oncol. 2019 Dec;30(12):e3. doi: 10.1093/annonc/mdw180. Epub 2016 May 2. Ann Oncol. 2019. PMID: 27141017 No abstract available.
Targeting polo-like kinase: learning too little too late?
Olmos D, Swanton C, de Bono J. Olmos D, et al. J Clin Oncol. 2008 Dec 1;26(34):5497-9. doi: 10.1200/JCO.2008.18.6585. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955441 No abstract available.
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. Attard G, et al. Among authors: olmos d. J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470933 Free PMC article. Clinical Trial.
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. Reid AH, et al. Among authors: olmos d. J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159823 Free PMC article. Clinical Trial.
Targeting IGF-1R: throwing out the baby with the bathwater?
Basu B, Olmos D, de Bono JS. Basu B, et al. Among authors: olmos d. Br J Cancer. 2011 Jan 4;104(1):1-3. doi: 10.1038/sj.bjc.6606023. Br J Cancer. 2011. PMID: 21206496 Free PMC article. No abstract available.
184 results